Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib vs Best Supportive Care in Elderly AML (F.I.G.H.T. AML 301)
NCT00093990Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Tipifarnib with Best Supportive Care (2 arms). Primary endpoint: Overall Survival. Started Jan 2004; status: completed.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00093990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093990.